Everest MED (01952) rose more than 6%, gaining 5.85% to HK$30.42 at the time of writing, with a turnover of HK$99.14 million. The company announced that Nefecon will present 23 new research findings at the 63rd European Renal Association Congress (ERA 2026), including 11 oral presentations and 12 e-posters. Among these findings, 21 are from real-world studies in China, covering multiple key dimensions such as causal treatment, early intervention, long-term management, management across different stages of chronic kidney disease (CKD), and refractory IgA nephropathy. Previously, Changjiang Securities issued a research report stating that Everest MED's commercialization capabilities have been preliminarily validated. The company is accelerating the introduction of late-stage and commercial assets through business development to rapidly expand its therapeutic areas and revenue streams, entering a virtuous cycle driven by commercialization. Its profitability continues to improve, laying a solid foundation for achieving its long-term strategic goals.